Targeting the PD-1/PD-L1 Axis in Human Vitiligo
Autoreactive CD8+ T cells play a pivotal role in melanocyte destruction in autoimmune vitiligo. Immunotherapy for melanoma often leads to autoimmune side-effects, among which vitiligo-like depigmentation, indicating that targeting immune checkpoints can break peripheral tolerance against self-antige...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-11-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2020.579022/full |
| id |
doaj-259d75f634c448bc80266435ae8f11d2 |
|---|---|
| record_format |
Article |
| spelling |
doaj-259d75f634c448bc80266435ae8f11d22020-11-25T03:59:45ZengFrontiers Media S.A.Frontiers in Immunology1664-32242020-11-011110.3389/fimmu.2020.579022579022Targeting the PD-1/PD-L1 Axis in Human VitiligoMarcella Willemsen0Cornelis J. M. Melief1Marcel W. Bekkenk2Rosalie M. Luiten3Department of Dermatology and Netherlands Institute for Pigment Disorders, Amsterdam University Medical Centers, location AMC, University of Amsterdam, Cancer Center Amsterdam, Amsterdam Infection & Immunity Institute, Amsterdam, NetherlandsISA Pharmaceuticals, Leiden, NetherlandsDepartment of Dermatology and Netherlands Institute for Pigment Disorders, Amsterdam University Medical Centers, location AMC, University of Amsterdam, Cancer Center Amsterdam, Amsterdam Infection & Immunity Institute, Amsterdam, NetherlandsDepartment of Dermatology and Netherlands Institute for Pigment Disorders, Amsterdam University Medical Centers, location AMC, University of Amsterdam, Cancer Center Amsterdam, Amsterdam Infection & Immunity Institute, Amsterdam, NetherlandsAutoreactive CD8+ T cells play a pivotal role in melanocyte destruction in autoimmune vitiligo. Immunotherapy for melanoma often leads to autoimmune side-effects, among which vitiligo-like depigmentation, indicating that targeting immune checkpoints can break peripheral tolerance against self-antigens in the skin. Therapeutically enhancing immune checkpoint signaling by immune cells or skin cells, making self-reactive T cells anergic, seems a promising therapeutic option for vitiligo. Here, we review the current knowledge on the PD-1/PD-L1 pathway in vitiligo as new therapeutic target for vitiligo therapy.https://www.frontiersin.org/articles/10.3389/fimmu.2020.579022/fullvitiligoprogrammed cell death 1 receptorB7-H1 antigenimmune toleranceautoimmunity |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Marcella Willemsen Cornelis J. M. Melief Marcel W. Bekkenk Rosalie M. Luiten |
| spellingShingle |
Marcella Willemsen Cornelis J. M. Melief Marcel W. Bekkenk Rosalie M. Luiten Targeting the PD-1/PD-L1 Axis in Human Vitiligo Frontiers in Immunology vitiligo programmed cell death 1 receptor B7-H1 antigen immune tolerance autoimmunity |
| author_facet |
Marcella Willemsen Cornelis J. M. Melief Marcel W. Bekkenk Rosalie M. Luiten |
| author_sort |
Marcella Willemsen |
| title |
Targeting the PD-1/PD-L1 Axis in Human Vitiligo |
| title_short |
Targeting the PD-1/PD-L1 Axis in Human Vitiligo |
| title_full |
Targeting the PD-1/PD-L1 Axis in Human Vitiligo |
| title_fullStr |
Targeting the PD-1/PD-L1 Axis in Human Vitiligo |
| title_full_unstemmed |
Targeting the PD-1/PD-L1 Axis in Human Vitiligo |
| title_sort |
targeting the pd-1/pd-l1 axis in human vitiligo |
| publisher |
Frontiers Media S.A. |
| series |
Frontiers in Immunology |
| issn |
1664-3224 |
| publishDate |
2020-11-01 |
| description |
Autoreactive CD8+ T cells play a pivotal role in melanocyte destruction in autoimmune vitiligo. Immunotherapy for melanoma often leads to autoimmune side-effects, among which vitiligo-like depigmentation, indicating that targeting immune checkpoints can break peripheral tolerance against self-antigens in the skin. Therapeutically enhancing immune checkpoint signaling by immune cells or skin cells, making self-reactive T cells anergic, seems a promising therapeutic option for vitiligo. Here, we review the current knowledge on the PD-1/PD-L1 pathway in vitiligo as new therapeutic target for vitiligo therapy. |
| topic |
vitiligo programmed cell death 1 receptor B7-H1 antigen immune tolerance autoimmunity |
| url |
https://www.frontiersin.org/articles/10.3389/fimmu.2020.579022/full |
| work_keys_str_mv |
AT marcellawillemsen targetingthepd1pdl1axisinhumanvitiligo AT cornelisjmmelief targetingthepd1pdl1axisinhumanvitiligo AT marcelwbekkenk targetingthepd1pdl1axisinhumanvitiligo AT rosaliemluiten targetingthepd1pdl1axisinhumanvitiligo |
| _version_ |
1724453089608466432 |